Solid Biosciences Inc.
SLDBNASDAQHealthcare● Active
$6.44
$-0.26(-3.88%)
Market Cap$501741688
P/E Ratio—
52W High$8.866
52W Low$3.675
Solid Biosciences Inc. (SLDB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SLDB · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.01B | $0.01B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | ($0.00B) | ($0.00B) | $0.01B | $0.01B |
| Gross Margin %(computed) | — | — | — | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.14B | $0.10B | $0.08B | $0.08B | $0.06B |
| G&A Expenses | $0.04B | $0.03B | $0.03B | $0.03B | $0.03B |
| Total Operating Expenses | $0.18B | $0.13B | $0.10B | $0.11B | $0.09B |
| Operating Income | ($0.18B) | ($0.13B) | ($0.10B) | ($0.11B) | ($0.07B) |
| Operating Margin %(computed) | — | — | — | — | -530.50% |
| Interest Income | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.17B) | ($0.12B) | ($0.10B) | ($0.09B) | ($0.07B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.17B) | ($0.12B) | ($0.10B) | ($0.09B) | ($0.07B) |
| Net Margin %(computed) | — | — | — | — | -530.01% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.99 | $-3.06 | $-4.83 | $-10.10 | $-10.14 |
| Wtd Avg Shares | 0.09B | 0.04B | 0.02B | 0.01B | 0.01B |
| EBITDA | ($0.18B) | ($0.12B) | ($0.09B) | ($0.10B) | ($0.07B) |
| EBITDA Margin %(computed) | — | — | — | — | -508.74% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Solid Biosciences Inc. data
About Solid Biosciences Inc. (SLDB) Income Statement
Solid Biosciences Inc. (SLDB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SLDB reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.17B) — a net profit margin of —.
Frequently asked questions
SLDB · 4 questionsSolid Biosciences Inc. (SLDB) reported revenue of $0.00B for 2025, down —% year-over-year.
SLDB revenueSLDB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08